E1912 and other trials spur emergence of small molecule-inhibitor therapies for chronic lymphocytic leukemia
Targeted Oncology
By Benjamin Holmes, DVM
The phase 3 E1912 trial .led to the development of small molecule inhibitor–targeted therapies with tyrosine kinase inhibitors against BTK and PI3K and inhibitors of BCL2